http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Twist Bioscience Collaborates With Beyond Earth to Launch Artwork Stored in DNA Into Space
-
Twist Bioscience to Host Virtual Biopharma Analyst & Investor Event on October 23, 2020
-
Twist Bioscience Corporation (TWST), Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies
-
Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies
-
Emily Leproust, Ph.D., to Receive 2020 Rosalind Franklin Award
-
Twist Bioscience to Present at Upcoming Virtual Investor Conferences
-
Twist Bioscience Corporation (TWST) Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
-
Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
-
Twist Bioscience Synthetic DNA Stores New Netflix Original Series ‘BIOHACKERS’
-
Twist Bioscience Reports Third Quarter Fiscal 2020 Financial Results
-
Seismic Bio Partners With Twist Bioscience for Discovery and Optimization of Antibodies
-
Twist Bioscience to Report Fiscal 2020 Third Quarter Financial Results on Thursday, August 6, 2020
-
Twist Bioscience Corporation (TWST) Launches Two SARS-CoV-2 Antibody Panels to Expedite Research for COVID-19
-
Twist Bioscience Launches Two SARS-CoV-2 Antibody Panels to Expedite Research for COVID-19
-
Twist Bioscience Appoints Erin Smith Senior Vice President, Government Affairs and Public Policy
-
Twist Bioscience Launches Synthetic Controls for Respiratory Viruses
-
Twist Bioscience (TWST) Customer VUMC Announces Publication of Positive Preclinical Results on Neutralizing Antibodies as Potential Therapy for Preventing and Treating COVID-19
-
Twist Bioscience Customer Vanderbilt University Medical Center (VUMC) Announces Publication of Positive Preclinical Results on Neutralizing Antibodies as a Potential Therapy for Preventing and Treatin
-
Takeda (TAK) Partners with Twist Bioscience (TWST) to Expand Biologics Discovery Capabilities
-
Takeda Partners with Twist Bioscience to Expand Biologics Discovery Capabilities
-
Twist Bioscience Adds Respiratory Virus Panel to Infectious Disease Product Line
-
Twist Bioscience Corporation (TWST) Announces Expanded Offering of Synthetic SARS-CoV-2 RNA Controls
-
Twist Bioscience Expands Offering of Synthetic SARS-CoV-2 RNA Controls
-
Twist Bioscience to Join Proteona in Global Alliance to Protect Immunocompromised Patients From COVID-19 Infection
-
Twist Bioscience to Present at the Jefferies Virtual Healthcare Conference
-
Twist Bioscience to Participate in the UBS Virtual Global Healthcare Conference
-
Twist Bioscience Reports Second Quarter Fiscal 2020 Financial Results
-
Twist Bioscience Corporation (TWST) Identifies Competitive Antibodies for SARS-CoV-2
-
Twist Bioscience Identifies Competitive Antibodies for SARS-CoV-2
-
Twist Bioscience to Report Fiscal 2020 Second Quarter Financial Results on Thursday, May 7, 2020
-
Twist Bioscience Expands Flexibility of Clonal Genes for Pharmaceutical, Biotechnology and Industrial Chemical Research
-
Twist Bioscience Partners with Vanderbilt University Medical Center to Supply Critical Products and Identify Antibody Therapeutics for COVID-19
-
Twist Bioscience (TWST) Says its Synthetic SARS-CoV-2 RNA Controls Added to FDA Website as Reference Materials
-
Twist Bioscience Synthetic SARS-CoV-2 RNA Controls Added to FDA Website as Reference Materials
-
Twist Announces Availability of Next-Generation Sequencing Target Enrichment Panel for SARS-CoV-2/COVID-19 Research
-
Twist Bioscience (TWST) Announces Availability of Synthetic SARS-CoV-2 RNA Controls
-
Twist Bioscience Announces Availability of Synthetic SARS-CoV-2 RNA Controls
-
Twist Bioscience and SOPHiA GENETICS Collaborate to Offer Optimized Genomic Solutions
-
Twist Bioscience to Present at the Cowen 40th Annual Health Care Conference
-
Twist Bioscience and Miroculus Agree to Collaborate on Next-Generation Sequencing Target Enrichment and Library Preparation Tools for Clinical Research
-
Twist Bioscience Launches New NGS Solutions, Highlights Customers at 2020 Advances in Genome Biology and Technology Conference
-
GenapSys Partners With Twist Bioscience to Bring Next-Generation Sequencing Target Enrichment and Library Preparation to World’s Most Accessible Highly Accurate Sequencer
-
Twist Bioscience Now ISO 27001:2013 Certified for Information Security Management System
-
Twist Bioscience Corporation (TWST) Confirms Settlement with Agilent (A)
-
Twist Bioscience Reports First Quarter Fiscal 2020 Financial Results
-
Twist Bioscience Announces Settlement Agreement with Agilent
-
CORRECTING and REPLACING Twist Bioscience Announces Completion of $50 Million Offering Priced At-The-Market
-
Twist Bioscience Corporation (TWST) Announces Completion of $50 Million Registered Direct Offering of Common Stock
-
Twist Bioscience Announces Completion of $50 Million Registered Direct Offering Priced At-The-Market
-
Twist Bioscience to Report Fiscal 2020 First Quarter Financial Results on Thursday, February 6, 2020

